Scipher Medicine Announces PrismRA^® Met Primary and Secondary Endpoints in Prospective Observational Study Predicting Inadequate Response to World’s Largest-Selling Drug Class, TNFi

Jun 24, 2021

Blood Test Predicts TNFi Response in Patients Both Naïve to and Experienced with TherapyProviders Can Access Patient-Specific Data for Optimized Therapy Selection JUNE 24, 2021 – WALTHAM, MA – Scipher Medicine, a precision immunology company matching...

Scipher Medicine Presents New Data at the European League Against Rheumatism (EULAR) 2021 Further Validating PrismRA^® Test

Jun 15, 2021

Molecular signature test predicts likelihood of non-response to adalimumab or etanercept, two of the world’s most expensive medications, in an independent validation cohortPrismRA demonstrates a more efficient therapy selection protocol beyond current standardThree...

Scipher Medicine and Leading Medical Researchers in Network and Data Science Compress Time to Identify Covid-19 Treatments from Years to Months

Jun 8, 2021

Study demonstrates Scipher Medicine’s ability to analyze patient data to identify novel treatments.Scipher will focus on pharma collaborations in autoimmune diseases. June 8, 2021 – WALTHAM, MA – Scipher Medicine, a precision immunology company matching patients with...

Scipher Applies Spectra^TM Platform to Discover Drugs Targeting Autoimmune Patients Refractory to Existing Therapies

May 4, 2021

– Leverages large genomic database from Scipher’s testing business- Proven SpectraTM platform brings precision therapeutics to autoimmune diseases.- Program commercialized through pharma partnerships. MAY 4, 2021 – WALTHAM, MA – Scipher Medicine, a precision...

Scipher Medicine Announces $82 Million Financing

Mar 23, 2021

-aMoon and Northpond Ventures led the round.-Additional investors include Echo Health Ventures, Khosla Ventures and Alumni Ventures.-Financing will support commercialization of precision medicine PrismTM portfolio of blood tests and data partnerships in autoimmune...

WellDyne Partners with Scipher Medicine to Improve Patient Outcomes and Lower Costs for Rheumatoid Arthritis Care

Feb 11, 2021

New PrismRA® blood test enables providers to identify optimal approach to rheumatoid arthritis treatment FEBRUARY 11, 2021 – WALTHAM, MA – Scipher Medicine, a precision immunology company matching patients with their most effective therapy, today announced...